此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Effects of Aerobic Exercise in Patients With Pre-diabetes

2014年7月16日 更新者:Sabyasachi Sen, MD、Baystate Medical Center

The Effect of Controlled Aerobic Exercise on Endothelial Dysfunction and Vascular Reactivity in Patients With Pre-diabetes: A Crossover Pilot Study

It is well known that diabetes and excessive or high blood sugars causes blood vessel and blood cell damage. It is also possible, then, that people with pre-diabetes may also start to have blood vessel and blood cell damage as the blood sugars rise from the normal range into the diabetic range. In addition to looking at potential damage, the question is whether or not this damage improves with exercise. This study aims to look at blood vessel and blood cells in three different ways by 1) looking at how the blood vessel responds to "sheer force" (a blood pressure cuff pumped up and then released after a few minutes). This is done by ultrasound. 2) By looking at blood tests such as blood sugar, cholesterol, and inflammation and 3) By looking at certain blood cells in the lab, how long they live and the number of cells left after a certain number of days, and again, if this improves with exercise.

研究概览

详细说明

  • To refine a non-invasive test for endothelial dysfunction. The investigators will examine the flow response to sheer-stress induced by the relief of pressure exerted with a blood pressure cuff on the brachial artery, measuring flow responses with Doppler. This is a measure of local nitric oxide production from endothelial cells which is known to be impaired in diabetics, normal in non-diabetics, but unknown in prediabetics.
  • To measure in the same individuals indicators of glucose metabolism abnormalities including fasting blood glucose, HbA1C, insulin sensitivity by homeostasis model assessment-estimated insulin resistance (HOMA-IR) and insulin levels.
  • To measure Endothelial Progenitor Cell (EPC) count, viability, gene expression of key genes such as endothelial nitric oxide synthase (eNOS), von-Willebrand's Factor (vWF) and adhesion molecules such platelet-endothelial cell adhesion molecule-1 (PECAM-1 or CD31), cadherin such as Vascular-Endothelial cadherin (VE-cadherin)or CD (cell surface marker)-144, growth factors such as vascular-endothelial growth factor (VEGF)and Insulin like growth factor (IGF-1)in the EPCs from pre-diabetes subjects pre and post exercise.
  • Correlate the glucose metabolism abnormalities with potential causative factors of endothelial dysfunction by studying EPC functions such as migration and tube formation and susceptibility to apoptosis in moderate hyperglycemia. Apoptosis assay will be done by Flow Cytometry analysis using Annexin V- Propidium-iodide dye.
  • Subjects will be randomized to the intervention (structured exercise) or continuation of their usual life style (non-exercise, sedentary)group.

In both arms of the study, subjects will be encouraged to adhere to the standard dietary advice that all pre-diabetic patients receive as part of their standards of care, irrespective of design arm they will be in.

The investigators expect exercise to improve flow-mediated vasodilatation, EPC colony count and function, along with better key gene expressions noted by Real Time-qualitative polymerase chain reaction (PCR).

  • Assess the effects of the intervention comparing them to the findings in each individual, in a paired manner.
  • After a washout period, individuals will be crossed over to see whether the effects of the intervention are reversed and to demonstrate that the difference between controls and intervention subjects was due to the aerobic exercise intervention, and not due to random differences

研究类型

介入性

注册 (预期的)

30

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Massachusetts
      • Springfield、Massachusetts、美国、01199
        • Baystate Medical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

20年 至 70年 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Prediabetic

    • Impaired fasting glucose (100-125mg/dl)
    • Impaired glucose tolerance (2' post between 140-199mg/dl)
    • HbA1C 5.7-6.4 mg/d (inclusive)
  • Exercise Naive
  • BMI between 20-39.9
  • Nutritional Counseling prior to participation with CDE/RD
  • Willing to wear activity monitor
  • Willing to keep a dietary log

Exclusion Criteria:

  • Pace maker or other implanted device that might have interference with Tanita scale
  • Any contraindication to moderate exercise
  • Previous coronary disease or cerebrovascular event active or clinically significant coronary vascular disease, or peripheral vascular disease
  • Diabetes
  • Uncontrolled hypertension (SBP > 140 or DBP > 90 on 3 separate occasions) ACE's or ARB's
  • Premature familial CAD (Father < 55years____ Mother <65years)
  • HDL < 40mg/dl
  • Triglycerides >400mg/dl
  • Any new lipid lowering medication started in the past 6 months
  • Framingham Risk Score two or more

    1. Smoking
    2. Hypertension (B/P > 140/90 or on antihypertensives)
    3. HDL < 40mg/dl
    4. Age men >45years or women >55years
  • Low hematocrit ( or hemoglobinopathies that may impair exercise tolerance) or abnormal CBC
  • Uncontrolled hypo/hyperthyroidism
  • Active smoking
  • Liver disease ( alt or AST> 2.5's UNL)
  • Moderate or Severe Kidney disease, current or history
  • Pancreatitis, current or history
  • Any medication started in the last 3 months
  • Active non healing wounds
  • Recent Surgery in the last 3 months
  • Anti-inflammatory disease, current or history
  • Regular use of anti-inflammatory drugs
  • CA
  • Alcoholism
  • Women who are pregnant or intending to become pregnant
  • Oral or Injectable antidiabetic medication
  • Post menopausal women on hormone replacement
  • Any steroid medication (oral, inhaled, injected or nasal)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
其他:Prediabetes with exercise
150 minutes of moderate exercise per week
150 minutes of moderate exercise per week
其他:Prediabetes without exercise
Pre-study activity level (i.e. no exercise)
Pre-study activity level (i.e. no exercise)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Measures of Endothelial Function by studying number, function and gene expression of endothelial progenitor cells (identified as CD34+ cells)
大体时间:16 weeks per patient
A. Number of viable CD34 +ve cells at Day-0 and viability assay. B. Colony Formation count assay at Day-5, pre and post exercise. C. We will test CD34+ cell migration, adhesion and tube formation properties. D. Gene expression in CD34+ cells of critical endothelial function and inflammatory genes will be measured: eNOS, vWF and PECAM1, VE-cadherin, VEGF-A, Superoxide dismutase (SOD)-1, 2 and 3, Catalase, Interleukin (IL)-6, Tumor Necrosis Factor (TNF alpha), P53, P21, PUMA, Bcl2 [Apoptosis genes] will also be noted
16 weeks per patient

次要结果测量

结果测量
措施说明
大体时间
Measures of Vacular Reactivity
大体时间:16 weeks
A) Measure Brachial reactivity through shear-stress using flow mediated dilatation (FMD) B). Measure Arterial Stiffness measure pre and post exercise. C) Measure Carotid Intima Media Thickness will be measured at each time point
16 weeks

其他结果措施

结果测量
措施说明
大体时间
Measures of Insulin Sensitivity by measuring inflammatory molecules as a surrogate of insulin resistance
大体时间:16 weeks

We will measure:

A. plasma measurements of cytokines, including C - reactive protein, E-selectin, IL-6, IL-10, thrombin, leptin, adiponectin, fasting glucose, fasting insulin and fasting lipid profile from subjects are expected to reflect endothelial inflammation.

B. Insulin sensitivity will be evaluated at baseline and weeks 6, 10 and16 using the HOMA ratio, calculated from individual serum measures (fasting glucose* insulin/405) C.Adiposity will be measured at baseline and at weeks 6, 10, and 16 using the Tanita Body Composition Analyzer scale, measured as percentage body fat D. Resting energy expenditure as measures of indirect calorimetry for basal metabolic rate measures (BMR).

16 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Sabyasachi Sen, MD, PhD、Baystate Medical Center

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2010年3月1日

初级完成 (实际的)

2013年5月1日

研究完成 (实际的)

2013年5月1日

研究注册日期

首次提交

2013年5月9日

首先提交符合 QC 标准的

2013年5月20日

首次发布 (估计)

2013年5月23日

研究记录更新

最后更新发布 (估计)

2014年7月17日

上次提交的符合 QC 标准的更新

2014年7月16日

最后验证

2014年7月1日

更多信息

与本研究相关的术语

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

Exercise的临床试验

3
订阅